Insights & Perspectives

Filter by










Therapeutic Area / Research

Year Starting

Year Ending

Search Insights:
Showing 1 to 10 of 363
Filter by: Unfiltered

Blog Post | Jan 20, 2015

Does Cyramza RAISE the bar in second-line CRC, or do efficacy and cost hold it back?

Oncology Conference Insight: ASCO GI --- Patients with metastatic colorectal cancer (mCRC) are typically treated at some point with at least one angiogenesis inhibitor. According to Kantar Health’s CancerMPact® Treatment Architecture U.S. data, Avastin® (bevacizumab, Genentech/Roche) is offered to approximately one-half of KRAS wild-type chemotherapy-naïve patients and three-quarters of KRAS mutated chemotherapy-naïve patients in the first-line setting. In the second- or third-line setting, patients might be treated with Avastin, Zaltrap® (ziv-aflibercept, Sanofi) or Stivarga® (regorafenib, Bayer/Onyx).

Read more | Share

Blog Post | Jan 16, 2015

Immunotherapy: Shining a Light on the Gastric Cancer Landscape

Oncology Conference Insight: ASCO GI --- Designated as a “breakthrough therapy” by the FDA for both advanced and unresectable malignant melanoma and advanced non-small cell lung cancer (NSCLC), and approved by the U.S. Food and Drug Administration (FDA) in September 2014 for advanced pretreated metastatic melanoma, the immune checkpoint inhibitor Keytruda® (pembrolizumab, Merck) has also shown promise for several other indications including (but not limited to) head and neck cancer, Hodgkin’s lymphoma and triple-negative breast cancer (TNBC).

Read more | Share

Podcast | Jan 8, 2015

Is Pharma Brand Marketing Dead?

Mark Sales discusses pharma brand marketing, product marketing, B2B vs. B2C, and how pharma marketers can make improvements in traditional areas of weakness.

Video | Dec 15, 2014

Patient Affordability – The Ongoing Crisis

Debbie Warner leads a panel discussing patient affordability - the ongoing crisis and opportunities for pharma

Watch | Share

Blog Post | Dec 12, 2014

The immunotherapy wave has finally hit the shores of the breast cancer landscape

Read more | Share

Newsletter | Dec 11, 2014

Kantar Health Catalyst, December 2014

Download the Catalyst newsletter to read our latest insights on privacy issues in Big Data, the oncology pipeline, and patient research.

Read more | Share

Case Study | Dec 9, 2014

Using gamification techniques to improve a multinational online quantitative survey

A multi-national pharmaceutical company increased engagement on a long-running physician survey by applying gamification techniques. The gamified survey brought new insights and actionable recommendations for our client that ultimately influenced the client's brand strategy.

Read more | Share

Blog Post | Dec 9, 2014

The battlefield extends into hematologic malignancies – continuing the race between PD-1-targeted therapeutics

Oncology Conference Insight: ASH 2014 --- Immune checkpoints in the Programmed Death -1 (PD-1) pathway have critical roles in balancing the co-stimulatory and co-inhibitory signals that regulate human self-tolerance and control the amplitude and duration of T‑cell responses. PD-1 is a key immune checkpoint receptor expressed on activated T-cells. Binding of PD-1 to its ligand (PD-L1) results in suppression of the immune response and tumor cells can manipulate this critical pathway to elude attack by tumor-infiltrating T-cells.

Read more | Share

Blog Post | Dec 9, 2014

Adcetris continues to advance outcomes in relapsed/refractory Hodgkin’s lymphoma

Oncology Conference Insight: ASH 2014 --- Hodgkin’s Lymphoma (HL) represents one of the more successful stories in oncology. The four-regimen combination of adriamycin, bleomycin, vinblastine and dacarbazine (ABVD) is standard of care for newly-diagnosed patients, and prognosis is excellent for patients who respond, demonstrating a five-year overall survival of approximately 80%.

Read more | Share

Blog Post | Dec 8, 2014

Something to ASPIRE to? Kyprolis + RevDex combination in relapsed/refractory multiple myeloma

Oncology Conference Insight: ASH 2014 --- Proteasome inhibitors and immunomodulators (IMiDs) are the mainstay of therapy for multiple myeloma. For years, treatment has relied on Velcade® (bortezomib, Millennium/Takeda/Johnson & Johnson) and Revlimid® (lenalidomide, Celgene) as part of first-line and second-line therapy, usually in sequence. Recently, two advances have changed this paradigm.

Read more | Share
Page  < 123456789 >